| (Values in U.S. Thousands) | Dec, 2017 | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 |
| Sales | 21,300 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | +100.00% |
| Net Income | -148,880 | -72,400 | -35,880 | -20,670 | -10,290 |
| Net Income Growth | -105.64% | -101.78% | -73.58% | -100.87% | -102.73% |
Loxo Oncology CS (LOXO)
234.80 +0.14 (+0.06%) 02/15/19 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime - - (-) -
for Fri, Feb 15th, 2019
Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut.
Fiscal Year End Date: 12/31